Medical Devices Startups

Owlstone Medical develops a breath-based diagnostic platform for non-invasive disease detection across respiratory conditions, cancers, and digestive health. The company serves academic, clinical, and pharmaceutical research partners seeking to develop breath biomarker applications for precision medicine and early diagnosis.

2 investors

Oxford Biomedica is a biopharmaceutical contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, lentiviral vector technologies, and bioprocessing solutions. The company provides manufacturing, development, and technical services to clients developing advanced therapies.

2 investors

Oxford Brain Diagnostics provides CDM Insights, a clinical software platform that analyzes MRI scans to detect and monitor microstructural changes in the brain for early diagnosis of neurodegenerative conditions. The platform integrates with standard hospital MRI systems and delivers quantitative brain assessment reports to clinicians within 12 hours.

2 investors

Pacertool develops a precision medicine system (PaCRTool) focused on heart failure therapy, aimed at helping clinicians select suitable patients, optimize treatment, and measure response. It positions its technology within cardiac care and medical devices for heart failure treatment.

2 investors

Pacific Biosciences develops long-read DNA and RNA sequencing platforms and kits for genomics research, including whole genome, targeted, epigenetic, and RNA sequencing applications. The company serves research institutions, clinical laboratories, and diagnostic organizations in genomics and life sciences.

2 investors

PainTEQ develops medical devices and implants for sacroiliac joint dysfunction, offering solutions ranging from biologicalbone allografts to titanium implants as alternatives to injections or fusion surgery. The company focuses exclusively on sacroiliac joint treatment for patients and physicians.

2 investors

Panacea provides FDA regulatory consulting and approval services for medical device and diagnostic companies, combining ex-FDA expertise with AI-powered technology to accelerate the regulatory pathway from strategy to market approval.

2 investors

Pandorum Technology develops tissue engineering and regenerative medicine products using proprietary stem cell and exosome platforms to address corneal dystrophies, lung disorders, and liver diseases. The company creates bio-engineered functional tissues through cell engineering, 3D printing, and cell-free therapies for medical research and therapeutic applications.

2 investors

Pangaea Data provides an AI-powered platform that analyzes electronic health records and clinical guidelines to identify untreated and under-treated patients across prevalent and rare conditions. The platform processes unstructured and structured EHR data with clinically validated reasoning to help healthcare providers discover patient needs with privacy preservation and no disruption to existing workflows.

2 investors

PANTHERx Rare is a specialty pharmacy focused exclusively on rare and orphan diseases, serving patients, their families, prescribers, and drug manufacturers across the U.S. It uses its RxARECARE model and SWFT technology platform to provide individualized medication management and patient support throughout the treatment journey.

2 investors

Parcel Health produces Parcel Prompts, custom-designed compostable printed materials for pharmacies and healthcare providers to include with medication orders and shipments. The product helps build patient trust while reducing waste through secure, visible messaging on prescription labels and package inserts.

2 investors

Parexel is a contract research organization (CRO) providing clinical development, regulatory consulting, and market access services for biopharmaceutical companies conducting clinical trials across phases I-IV globally. The company operates with a network of offices and specialized facilities across North America, Latin America, Europe, and Asia-Pacific.

2 investors

Path Fertility develops diagnostic tests for male reproductive health, using sperm epigenetics technology to identify subfertility that standard analysis misses. The tests enable earlier and more accurate diagnosis for couples pursuing fertility treatment.

2 investors

Pathfinder Med develops its patented ePATH catheter guidance platform for endovascular procedures in peripheral interventions and vascular access creation. The company designs and manufactures medical devices in-house, including at an ISO Class 7 cleanroom.

2 investors

PathoQuest develops iDTECT, a platform of Next Generation Sequencing (NGS) assays for biopharmaceutical quality control, offering animal-free viral safety testing and genetic characterization of cell banks and biologics. The company was acquired by Charles River Labs to expand its end-to-end biologics testing portfolio.

2 investors

PathPresenter is a digital pathology platform used for viewing, sharing, and managing pathology images in clinical, research, and educational settings. It serves pathologists and healthcare/medical organizations in the digital and computational pathology field.

2 investors

Patient21 develops a digital platform to help clinics operate and connect for value-based healthcare, removing administrative burdens from physicians to improve the doctor-patient relationship. The company serves outpatient clinics and healthcare providers across multiple medical specialties.

2 investors

Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps. Its phenotypic testing targets common infection sites to support faster, more focused antibiotic treatment in hospitals and combat antibiotic resistance.

2 investors

PEP-Therapy develops peptide-based therapeutic candidates for oncology, with a lead product in clinical trials targeting solid tumors including ovarian cancer and pancreatic cancer. The company uses an intracellular delivery technology platform to deliver peptides that restore apoptosis in cancer cells.

2 investors

PepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

2 investors

Peptinovo develops PALM™, a targeted drug-delivery platform that encapsulates chemotherapy drugs to deliver them directly to cancer cells while sparing healthy tissue, reducing side effects and enabling higher therapeutic doses. The technology mimics HDL cholesterol carriers that cancer cells naturally uptake, allowing selective destruction of tumors with improved safety profiles.

2 investors

Peptomyc is a biotech company developing MYC inhibitors for cancer treatment, based on the Omomyc molecule, and is advancing them through preclinical and clinical trials. It operates in oncology drug development, with its research group linked to the Vall d'Hebron Institute of Oncology in Barcelona, Spain.

2 investors

Peregrine is a global life science venture capital fund that invests in healthcare companies through strategic synergistic investments. The firm partners with entrepreneurs and established healthcare institutions to develop innovations that improve health outcomes and healthcare economics.

2 investors

Perfuze develops medical devices for the treatment of acute ischemic stroke, focused on addressing unmet clinical needs in mechanical thrombectomy. The company is a medical technology firm based in Ireland with clinical partnerships in the US and Europe.

2 investors